Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
4 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
By Katherine HamiltonVeracyte acquired Convergent Genomics, a bladder cancer treatment company, in a deal worth up to $180 million.The cancer diagnostics company said Monday that the deal will add Convergent's proprietary urinary tumor DNA technology to its product portfolio.The deal includes $150…
Veracyte entered into an Agreement and Plan of Merger to acquire Convergent Genomics, adding the UroAmp test and urine tumor DNA technology to its portfolio. The deal closed on September 14, 2026, with $150 million paid in cash at closing and up to $30 million in additional cash tied to milestones…
Veracyte, Inc. (NASDAQ: VCYT ), a leading cancer diagnostics company, today announced its acquisition of Convergent Genomics. The acquisition adds Convergent Genomics’ UroAmp platform, including its proprietary urinary tumor DNA (utDNA) technology, to Veracyte’s product portfolio. To date, UroAmp has been clinically va
VCYT - Veracyte Acquires Convergent Genomics, Expanding its Urology Diagnostics Portfolio with a Urinary Tumor DNA Testing Platform